Sarcoma

120 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Sarcoma
Treatment and conditionWhere it standsTrials
Abemaciclib + Irinotecan + Temozolomide for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for rhabdomyosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for sarcoma, ewingTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Doxorubicin hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Diagnostic Imaging Testing + Excisional Biopsy + Minimally Invasive Surgery + Pelvic Lymphadenectomy + Questionnaire Administration + Sentinel Lymph Node Mapping + Indocyanine Green for carcinosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy for osteosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide + VINORELBINE for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dacarbazine for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for dermatofibrosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Definitive radiotherapy for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DOCETAXEL + Hydroxychloroquine + Gemcitabine for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + oleclumab for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE + Temozolomide for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + BEVACIZUMAB + Paclitaxel for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Doxorubicin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Eribulin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + PEMBROLIZUMAB for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + TRASTUZUMAB DERUXTECAN for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 subcutaneous (SC) for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HS-20093 for osteosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Intensity-modulated radiation therapy (IMRT) for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + Temozolomide for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Iscador*P for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivonescimab for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, alveolarPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, embryonalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoidPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifileucel for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifileucel for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lurbinectedin for leiomyosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Naxitamab for sarcoma, ewingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neoadjuvant Radiation + Surgery + TALIMOGENE LAHERPAREPVEC for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
NIVOLUMAB + Catequentinib for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab + trabectedin for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onfekafusp alfa for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib for sarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for carcinosarcomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for rhabdomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for sarcoma, ewingPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrousPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoidPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for dermatofibrosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for histiocytoma, malignant fibrousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + TRABECTEDIN for leiomyosarcomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + TRABECTEDIN for liposarcoma, myxoidTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Regorafenib for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Siremadlin + PAZOPANIB for sarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talimogene laherparepvec + nivolumab + trabectedin for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for sarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for osteosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vinorelbine for rhabdomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1